Andrew Joseph , 2025-05-16 11:35:00
Contents
LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success stall in recent months, is stepping down as CEO, the company said Friday.
Jørgensen, who’s worked at Novo for more than 30 years and has been CEO for eight, will continue in the position for a period “to support a smooth transition to new leadership,” the company said.
The search for the next CEO is ongoing.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
